Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tall, P., Qamar, M. A., Batzu, L., Leta, V., Falup-Pecurariu, C., Ray Chaudhuri, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2023
Materias:
Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645607/
https://www.ncbi.nlm.nih.gov/pubmed/37126118
http://dx.doi.org/10.1007/s00702-023-02640-7
_version_ 1785147389365977088
author Tall, P.
Qamar, M. A.
Batzu, L.
Leta, V.
Falup-Pecurariu, C.
Ray Chaudhuri, K.
author_facet Tall, P.
Qamar, M. A.
Batzu, L.
Leta, V.
Falup-Pecurariu, C.
Ray Chaudhuri, K.
author_sort Tall, P.
collection PubMed
description Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD.
format Online
Article
Text
id pubmed-10645607
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-106456072023-11-14 Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease Tall, P. Qamar, M. A. Batzu, L. Leta, V. Falup-Pecurariu, C. Ray Chaudhuri, K. J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Review Article Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD. Springer Vienna 2023-05-01 2023 /pmc/articles/PMC10645607/ /pubmed/37126118 http://dx.doi.org/10.1007/s00702-023-02640-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Neurology and Preclinical Neurological Studies - Review Article
Tall, P.
Qamar, M. A.
Batzu, L.
Leta, V.
Falup-Pecurariu, C.
Ray Chaudhuri, K.
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title_full Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title_fullStr Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title_full_unstemmed Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title_short Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
title_sort non-oral continuous drug delivery based therapies and sleep dysfunction in parkinson’s disease
topic Neurology and Preclinical Neurological Studies - Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645607/
https://www.ncbi.nlm.nih.gov/pubmed/37126118
http://dx.doi.org/10.1007/s00702-023-02640-7
work_keys_str_mv AT tallp nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease
AT qamarma nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease
AT batzul nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease
AT letav nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease
AT faluppecurariuc nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease
AT raychaudhurik nonoralcontinuousdrugdeliverybasedtherapiesandsleepdysfunctioninparkinsonsdisease

Ejemplares similares